Much Ado About Descovy
A friend of mine, knows I enjoy sharing information about breakthroughs in the HIV medication world. As some one who has worked at the grassroots and has witnessed many wonders, I call upon you to read materials such as this. This is from the magazine called The Body. " A medical landmark that might call for fanfare -- a second drug to prevent HIV infection -- is receiving boos from HIV/AIDS advocates who say its rollout could be a step backward, not forward, in access to HIV prevention. In early October, the U.S. Food and Drug Administration (FDA) approved Descovy (emtricitabine/tenofovir alafenamide), manufactured by Gilead Sciences, for men who have sex with men and transgender women as a daily pill for pre-exposure prophylaxis, or PrEP. But the drug isn't approved for vaginal sex -- the company didn't test for it -- and that ignores a crucial at-risk part of the population, critics say. Gilead has been touting Descovy's safety -- inflating its safety, detrac...